Turnstone Biologics Q3 EPS $(1.00) Up From $(6.15) YoY; Cash, Cash Equivalents And Short-Term Investments $109.1M
Portfolio Pulse from Benzinga Newsdesk
Turnstone Biologics (NASDAQ:TSBX) reported Q3 losses of $(1.00) per share, a 83.74% increase over losses of $(6.15) per share from the same period last year. The company's cash, cash equivalents and short-term investments stand at $109.1M.
November 10, 2023 | 6:03 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Turnstone Biologics reported a significant decrease in losses YoY, which could be seen as a positive sign by investors. However, the company is still operating at a loss.
While the decrease in losses is a positive sign, the company is still operating at a loss, which could impact investor sentiment. The company's cash position is also a factor to consider.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100